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Aims: This 76-week, open-label, parallel-group study assessed the long-term safety of once-daily lixisenatide
monotherapy in Japanese patients with type 2 diabetes mellitus.
Methods: Patients were randomized to receive lixisenatide in a 2-step or a 1-step dose-increase regimen. The primary
objective was to assess the safety of lixisenatide at week 24 by a descriptive comparison of the 2- and 1-step groups.
Results: As expected with treatment with a glucagon-like peptide-1 agonist, nausea was the most common
treatment-emergent adverse event (2-step group: n = 12/33 [36.4%] vs 1-step group: n = 18/36 [50.0%] up to
week 24). In total, 5/33 patients (15.2%; 2-step group) and 2/36 patients (5.6%; 1-step group) prematurely
discontinued treatment up to week 24, mainly due to adverse events. Serious treatment-emergent adverse
events occurred in 2/33 patients (6.1%; 2-step group) versus 0/36 patients (0%; 1-step group) up to week 24.
Symptomatic hypoglycemia occurred in 2/33 patients (6.1%; 2-step group) versus 1/36 patients (2.8%; 1-step
group) up to week 24, with no severe events reported. Glycated hemoglobin, fasting plasma glucose, and body
weight were reduced from baseline at weeks 24 and 76.
Conclusion: In Japanese patients with type 2 diabetes mellitus, once-daily lixisenatide monotherapy was well
tolerated, with less nausea with the 2-step regimen.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The prevalence of diabetes is increasing both globally and in Japan.
A total of 7.1 million people (7.5% of the population) were reported
to have diabetes in Japan in 2012, which is estimated to increase to
10.2 million (12.0% of the population) by 2030 (International Diabetesre. Yutaka Seino has received
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Inc. This is an open access article uFederation, 2013). This increase in Japan is attributed to rising obesity
levels and a more sedentary lifestyle (Kawamori, 2002).
In addition to lifestyle interventions, patients with type 2 diabetes
mellitus (T2DM) often require glucose-lowering agent(s) to maintain
glycemic control. However, a number of treatment options currently
available are associated with hypoglycemia (e.g. sulfonylureas, insulin,
and meglitinides) and/or weight gain (e.g. sulfonylureas, insulin,
meglitinides, and thiazolidinediones), which may play a major role in
drug selection (Inzucchi et al., 2012; van Dieren et al., 2012).
Glucagon-like peptide-1 (GLP-1) receptor agonists are glucose-
lowering agents that stimulate insulin secretion in a glucose-dependent
manner, suppress glucagon release, and delay gastric emptying, with a
beneﬁcial effect on body weight and a low risk of hypoglycemia
(Drucker & Nauck, 2006; Meier, 2012; Shin, 2012). It has been
suggested that these agents may also preserve β-cell function (Seino,
Fukushima, & Yabe, 2010; Seino, Rasmussen, Clauson, & Kaku, 2012)
and prevent diabetes-related complications (Seino & Yabe, 2013).
GLP-1 receptor agonists may be particularly effective in Asian and
Japanese patients, as there is evidence to suggest an underlying GLP-1
insufﬁciency in this patient population (Seino, Fukushima, & Yabe,
2010; Yabe et al., 2010; Yabe et al., 2012). Furthermore, β-cell
dysfunction is considered to be the primary cause of T2DM in Japanese
patients (Namba et al., 2013), which may be confounded by the GLP-1nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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protection (Yabe & Seino, 2011).
Lixisenatide is a once-daily prandial GLP-1 receptor agonist for the
treatment of T2DM, and has been approved in Japan for the treatment
of T2DM insufﬁciently controlled on diet and exercise in combination
with sulfonylurea with or without biguanide, or with basal insulin
with or without sulfonylurea (Sanoﬁ, 2013). Lixisenatide has been
extensively evaluated in the phase III ‘GetGoal’ clinical trials program,
in which it was shown to be efﬁcacious and well tolerated in patients
with T2DM (Ahren et al., 2013; Fonseca et al., 2012; Pinget et al., 2013;
Riddle, Aronson, et al., 2013; Riddle, Forst, et al., 2013; Rosenstock
et al., 2013; Seino, Min, Niemoeller, Takami, & Investigators, 2012).
Lixisenatide improves glycemic control and has distinct effects on
postprandial plasma glucose owing to a delay in gastric emptying
(Horowitz et al., 2013; Lorenz et al., 2013). The effects of lixisenatide
in Japanese and other Asian patients were reported in a 24-week,
randomized controlled trial evaluating once-daily treatment of
lixisenatide in combination with basal insulin with or without
sulfonylurea (GetGoal-L-Asia study) (Seino, Min, Niemoeller, Takami,
& Investigators, 2012). In contrast to other GLP-1 receptor agonists
(Inagaki et al., 2011; Kaku et al., 2011; Onishi et al., 2012; Seino et al.,
2011), the long-term effects of lixisenatide treatment in Japanese
patientshavenotbeen reportedpreviously. TheGetGoal-Mono-Japan trial
reports the long-term safety for lixisenatidewhen used as amonotherapy
in Japanese patients with T2DM.
2. Materials and methods
2.1. Study design
This 76-week, randomized, open-label, parallel-group, multicenter
study was conducted in nine centers in Japan. The study consisted of a
screening period of up to 2 weeks, a 1-week run-in period, and a
52-week treatment period. Patients who completed the 52-week phase
entered a 24-week extension phase and continued the same treatment.
Patients were randomized in a 1:1 ratio to a 2-step (10 μg once daily for
1 week, 15 μg once daily for 1 week, then the maintenance dose of
20 μg once daily; n = 33) or a 1-step dose-increase regimen (10 μg
once daily for 2 weeks, then 20 μg once daily; n = 36) of lixisenatide,
administered subcutaneously once daily within 1 h before breakfast.
Patients were stratiﬁed by screening values of glycated hemoglobin
(HbA1c; b8.0%, ≥8.0%) and prior use of an oral antidiabetic drug (OAD)
within 3 months before screening. The study was approved by the
institutional review boards or ethics committees of the participating
centers, and was conducted in accordance with the principles of the
Declaration of Helsinki and Good Clinical Practice guidelines.
All participants provided written informed consent. An external and
independent Data Monitoring Committee supervised conduct of the
study. Possible allergic events were adjudicated by an external Allergic
Reaction Assessment Committee (ARAC).
2.2. Participants
Main entry criteria included patients in Japan with T2DM diagnosed
at least 2 months before the screening visit, not treated with an OAD in
the 3 months before screening, except treatment with sulfonylureas or
α-glucosidase inhibitors at a stable dose, which had to be stopped before
starting the single-blind, run-in phase. Exclusion criteria included insulin
use within 3 months prior to screening visit; fasting plasma glucose
(FPG) at screening N13.9 mmol/L (250 mg/dL); history of unexplained
pancreatitis, chronic pancreatitis, pancreatectomy, stomach/gastric
surgery or inﬂammatory bowel disease; amylase and/or lipase values
of more than three times the normal laboratory range; history of
metabolic acidosis, including diabetic ketoacidosis within 1 year prior to
screening; end-stage renal disease and/or patients on dialysis; history ofgastrointestinal disease associated with prolonged nausea and vomiting
within 6 months prior to screening.2.3. Safety and efﬁcacy measurements
The primary objective of the study was to assess the safety of
once-daily lixisenatide treatment up to week 24 by a descriptive
comparison of a 2- and 1-step dose regimen. Primary safety assessments
during the 24-week on-treatment period included: adverse events (AEs),
primarily treatment-emergent AEs (TEAEs) and serious TEAEs, symp-
tomatic hypoglycemia and severe symptomatic hypoglycemia, local
tolerability at injection site, allergic reactions, suspected pancreatitis,
vital signs (systolic/diastolic blood pressure [SBP/DBP]), serum amylase,
lipase and calcitonin, hematology, and serum chemistry. Symptomatic
hypoglycemia was deﬁned per protocol as an event with clinical
symptoms that were considered to result from a hypoglycemic episode,
with an accompanying plasma glucose b3.3 mmol/L (60 mg/dL), or
associated with prompt recovery after oral carbohydrate, intravenous
glucose, or glucagon administration if no plasma glucose measurement
was available. Severe symptomatic hypoglycemia was deﬁned as an
event with clinical symptoms that was considered to result from
hypoglycemia in which the patient required the assistance of another
person, and which was associated either with a plasma glucose level
of b2.0 mmol/L (36 mg/dL) or, if no plasma glucose measurement was
available, with prompt recovery with oral carbohydrate, intravenous
glucose, or glucagon injection.
The secondary objective of the study was to assess the overall
safety of once-daily lixisenatide treatment up to week 76 for the
pooled data from the 2- and 1-step dose regimens, and efﬁcacy at
weeks 24, 52, and 76, as assessed by change in HbA1c, FPG, and body
weight. HbA1c values were expressed as the National Glycohemoglobin
StandardizationProgramvalues, as recommendedby the JapanDiabetes
Society (Kashiwagi et al., 2012).2.4. Statistical analyses
The evaluation of AEs, clinical laboratory data, vital signs and
electrocardiogram data was descriptive. Analysis of primary safety
variables with 24-week data was performed for the 2- and 1-step
groups. Secondary analyses and assessment were performed on the
pooled data of the 2- and 1-step dose regimens based on the safety
data (combined group). The efﬁcacy analysis was performed using
descriptive statistics and here the results at baseline, at week 24 and
at week 76 time points are reported on observed cases in themodiﬁed
intent-to-treat population, which comprised all randomized patients
who received at least one dose of study drug and who had both a
baseline assessment and at least one post-baseline assessment of any
efﬁcacy variable. The safety population comprised all randomized
patients exposed to at least one dose of study drug.3. Results
3.1. Patients
A total of 75 patients were screened, of whom 69 patients were
randomized to one of the two dose-increase regimens (Fig. 1). During
the 24-week treatment period, 7/69 patients (10.1%) discontinued
from the study (n = 5/33 [15.2%] in the 2-step group and n = 2/36
[5.6%] in the 1-step group), the main reason being AEs. During the
whole 76-week study period, 22/69 patients (31.9%) in the combined
group discontinued study treatment, mainly due to AEs.
Patient demographic and baseline characteristics were well
matched between the two treatment groups in this generally non-obese
population (Table 1).
Patients screened
(n = 75)
Run-in
(n = 70)
Patients randomized
(n = 69)
2-step dose increase
(n = 33; 47.8%)
Patients discontinued
24-week treatment period
(n = 5; 15.2%)
Adverse event (n = 3; 9.1%)
Other reason (n = 2; 6.1%)
Patients discontinued
76-week treatment period
(n = 13; 39.4%)
Adverse event (n = 7; 21.2%)
Other reason (n = 6; 18.2%)
Patients completed
24-week treatment period
(n = 28; 84.8%)
Patients completed
76-week treatment period
(n = 20; 60.6%)
1-step dose increase
(n = 36; 52.2%)
Patients discontinued
24-week treatment period
(n = 2; 5.6%)
Adverse event (n = 2)
Patients discontinued
76-week treatment period
(n = 9; 25.0%)
Adverse event (n = 5; 13.9%)
Other reason (n = 4; 11.1%)
Patients completed
24-week treatment period
(n = 34; 94.4%)
Patients completed
76-week treatment period
(n = 27; 75%)
Screening period failures
(n = 5)
Run-in failures
(n = 1)
Fig. 1. Patient disposition.
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The proportion of patients with TEAEs was comparable between
the groups (Table 2). Up to week 24, serious TEAEs occurred in 2/33
patients (6.1%) in the 2-step group (one patient had gastroenteritis
and one patient had a skin laceration) and none of the patients in the
1-step group. Over the entire 76-week trial period, four serious TEAEs
occurred in 3/69 patients (4.3%) in the combined group (gastroen-
teritis, cataract, intervertebral disc protrusion, and skin laceration).
No deaths occurred during the study. TEAEs leading to treatment
discontinuation were reported for 3/33 patients (9.1%) in the 2-step
group, 4/36 patients (11.1%) in the 1-step group up to week 24 and
10/69 patients (14.5%) in the combined group up to week 76
(Table 2), with the majority of events being due to gastrointestinal
disorders (n = 4/69, 5.8%), primarily nausea (n = 3/69, 4.3%). In
addition, nausea was the most frequently reported TEAE (n = 12/33
[36.4%] in the 2-step group compared with n = 18/36 [50.0%] in the
1-step group up to week 24; n = 30/69 [43.5%] in the combined
group up to week 76; Table 2).
Nausea was reported more frequently during the ﬁrst 3 weeks of
treatment,with a relatively lowoccurrence fromweek 4 onwards (Fig. 2).Table 1
Baseline characteristics (safety population).
2-step regimen (n = 33)
Male, n (%) 30 (90.9)
Median age, years (range) 58.0 (40–73)
Median diabetes duration, years (range) 6.4 (0.6–29.5)
Mean HbA1c at screening, % (SD) 8.3 (0.9)
Randomized strata of screening HbA1c, n (%)
b8 14 (42.4)
≥8 19 (57.6)
Mean BMI, kg/m2 (SD) 25.2 (5.3)
Mean FPG, mmol/L (SD) 9.9 (1.9)
Mean SBP, mmHg (SD) 126.4 (12.6)
Mean DBP, mmHg (SD) 77.6 (9.0)
OAD use at screening, n (%) 16 (48.5)
Sulfonylurea 14 (42.4)
α-Glucosidase inhibitor 2 (6.1)
Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; FPG, fasting plasma g
pressure; SD, standard deviation.Themajority of the events of nauseaweremild (n = 24/69 [34.8%]), with
6/69 patients (8.7%) in the combined group having events reported as
moderate in intensity during the76-weekon-treatment period.No severe
events were reported. The majority of patients recovered without the
need to administer corrective treatment.
Vomiting was reported in 4/33 patients (12.1%) in the 2-step
group and in 1/36 patients (2.8%) in the 1-step group up to week 24.
No further patients reported vomiting during the remainder of the
76-week treatment period (combined group: n = 5/69 [7.2%] at week
76). Diarrhea was reported in 1/33 patients (3%) in the 2-step group
and in 3/36 patients (8.3%) in the 1-step group up to week 24, with no
additional events reported during the remainder of the 76-week trial
period (combined group: n = 4/69 [5.8%] at week 76; Table 2).
Symptomatic hypoglycemia (as deﬁned in the protocol) occurred
in 2/33 patients (6.1%) in the 2-step group compared with 1/36
patients (2.8%) in the 1-step group up to week 24 and 5/69 patients
(7.2%) in the combined group up to week 76 (Table 2), with no events
considered to be severe according to the protocol-deﬁned criteria.
Other safety assessments are also summarized in Table 2.
Injection-site reactions were reported for 3/33 patients (9.1%) in the
2-step group and 4/36 patients (11.1%) in the 1-step group during the1-step regimen (n = 36) Combined (n = 69)
28 (77.8) 58 (84.1)
61.0 (41–76) 61.0 (40–76)
7.6 (0.6–36.5) 7.3 (0.6–36.5)
8.2 (0.7) 8.3 (0.8)
17 (47.2) 31 (44.9)
19 (52.8) 38 (55.1)
24.8 (3.7) 25.0 (4.5)
9.2 (1.9) 9.5 (1.9)
127.9 (14.8) 127.2 (13.7)
76.9 (9.3) 77.2 (9.1)
18 (50.0) 34 (49.3)
17 (47.2) 31 (44.9)
1 (2.8) 3 (4.3)
lucose; HbA1c, glycated hemoglobin; OAD, oral antidiabetic agent; SBP, systolic blood
Table 2
Summary of outcome measures and safety assessments (safety population).
Time period Week 24 Week 24 Week 76
n (%) 2-step regimen (n = 33) 1-step regimen (n = 36) Combined (n = 69)
Patients with any TEAE 27 (81.8) 32 (88.9) 63 (91.3)
Patients with any serious TEAE 2 (6.1) 0 3 (4.3)
Patients with any TEAE leading to death 0 0 0
Patients with any TEAE leading to permanent treatment discontinuation 3 (9.1) 4 (11.1) 10 (14.5)
Patients with any gastrointestinal TEAEs 21 (63.6) 28 (77.8) 51 (73.9)
Nausea 12 (36.4) 18 (50.0) 30 (43.5)
Vomiting 4 (12.1) 1 (2.8) 5 (7.2)
Diarrhea 1 (3.0) 3 (8.3) 4 (5.8)
Patients with symptomatic hypoglycemiaa 2 (6.1) 1 (2.8) 5 (7.2)
Patients experiencing injection-site reactions
Any injection-site reaction 3 (9.1) 4 (11.1) 7 (10.1)
Blood pressure, mean change from baseline (SD)
SBP, mmHg −1.9 (12.4) −2.7 (10.8) 0.1 (12.3)
DBP, mmHg −0.1 (9.5) 0.2 (9.3) 0.2 (9.6)
Abbreviations: ARAC, Allergic Reaction Assessment Committee; DBP diastolic blood pressure; SBP, systolic blood pressure; SD, standard deviation; TEAE, treatment-emergent
adverse event.
n subset of total number of patients who met criterion in question at least once during treatment.
a According to the protocol deﬁnition.
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discontinuation of treatment (Table 2). No additional patients had
injection-site reactions during the remainder of the 76-week treatment
period. Allergic reaction positively adjudicated by the ARAC occurred in
1/33 patients (3.0%) in the 2-step group (asthma) and 2/36 patients
(5.6%) in the 1-step group (one event of rhinitis allergic and one of
urticaria). The urticaria event reported in the 1-step group was
adjudicated as possibly related to study treatment by the ARAC and
led to treatment discontinuation. An additional two patients had a TEAE
of allergic reaction positively adjudicated by the ARAC up to week 76 in
the combined group (one additional event of rhinitis allergic and one of
urticaria), neither of which were considered to be related to treatment.
No patient had a TEAE of increased blood calcitonin levels ≥20 ng/L. No
event of pancreatitis was reported during the study, and no patient had
lipase or amylase values of more than two times the normal laboratory
range. Additionally, SBP and DBP remained stable throughout the entire
treatment period (Table 2).0
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Mean HbA1c was reduced from baseline at week 24 for both the 2-
and the 1-step regimen (mean change from baseline: −0.99% [95%
conﬁdence interval (CI) –1.45 to−0.52] for the 2-step group vs−0.74%
[95% CI−1.02 to−0.46] for the 1-step group). For patients who stayed
on-treatment, this reduction was maintained in the combined group at
week 76 (−0.72% [95% CI−1.15 to−0.30]) (Fig. 3). A total of 17.4% of
patients in the 2-step group compared with 15.2% in the 1-step group
achieved HbA1c of ≤6.5% at week 24. In addition, 34.8% (2-step group)
versus 33.3% (1-step group) achieved HbA1c of b7.0%. Based on
observed cases, this effect was also maintained throughout the 76-week
study period (HbA1c ≤6.5 and b7%: 18.2 and 27.3%, respectively, in the
combined group at week 76).
At week 24, the mean changes from baseline in FPG were −1.16
and−0.56 mmol/L for the 2- and 1-step regimens, respectively. In the
combined group, themean change in FPGwas−0.46 mmol/L atweek 76.2
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in the 2-step group compared with −1.08 kg in the 1-step group.
Body weight further decreased to−1.58 kg in the combined group at
week 76.
4. Discussion
This open-label study in Japanese patientswith T2DMdemonstrated
that long-term treatment with once-daily lixisenatide monotherapy
was well tolerated. Safety and tolerability were maintained during
the entire 76-week study, and the frequency of serious TEAEs was
low (4.3%). The incidences of TEAEs and AEs leading to permanent
discontinuation of study treatment were generally similar for both the
2- and the 1-step dose regimens during the 24-week treatment period.
As observedwith other GLP-1 receptor agonists, themost frequently
reported AEs in this study were gastrointestinal in nature, predomi-
nantly nausea, with lower levels of vomiting and diarrhea. Nausea was
reported in fewerpatients in the 2-stepgroup comparedwith the1-step
group. Events generally occurred early on in treatment and decreased
over the treatment period. In the present study, the combined nausea
frequency throughout the 76-week study period (43.5%) was higher
than that observed with lixisenatide monotherapy in a 12-week study
in predominantly Caucasian patients (GetGoal-Mono study: 22.2%)
(Fonseca et al., 2012), but was consistent with the nausea levels
reported with lixisenatide treatment in combination with basal insulin
in a 24-week study in an exclusively Asian population (GetGoal-L-Asia
trial: 39.6%) (Seino, Min, Niemoeller, Takami, & Investigators, 2012).
In both the GetGoal-Mono and the GetGoal-L-Asia studies, nausea
generally occurred during the initial weeks of treatment and decreased
over the treatment period, which is consistent with what was observed
in the current study.
A meta-analysis of clinical trials of GLP-1 receptor agonists
highlighted the differences in risk of gastrointestinal AEs between
Asian and non-Asian patients, with a higher observed incidence
of nausea and vomiting in Asian patients, but a lower incidence of
diarrhea (Kim et al., 2014). However, the authors suggested that the
observed differences by study could be also explained by the tendency
towards lower body mass indexes in Asian populations compared
with non-Asian cohorts (Kim et al., 2014).
The incidence of nausea seen with lixisenatide monotherapy in this
study (36.4% in the 2-step group and 50.0% in the 1-step group at
24 weeks, 43.5% for the combined group at week 76) appears similar to
that seen in a 24-week study of exenatide 10 μg twice daily (with
sulfonylurea alone or combined with a biguanide or thiazolidinedione)
in Japanese patients (36.1%) (Kadowaki et al., 2011). Vomiting was
reported in 16.7% of patients at week 24 in the exenatide study
(Kadowaki et al., 2011); and in 7.2% of patients at week 76 in this study
(combined lixisenatide group). In a 24-week study of liraglutide oncedaily (as monotherapy) and a 26-week study of exenatide once weekly
(on a background of biguanide ± sulfonylurea ± thiazolidinedione),
both in Japanese patients, the incidence of nausea was 4.5% and 12.6%,
respectively (Inagaki et al., 2012; Seino, Rasmussen, Nishida, & Kaku,
2010). However, such comparisonsmust be interpreted carefully owing
to differences in the study designs, populations, and background
medications. Furthermore, the reported frequency of nausea can vary,
even for trials using the same GLP-1 receptor agonist (Buse et al., 2013;
Drucker et al., 2008).
In GetGoal-Mono-Japan, the incidence of symptomatic hypogly-
cemia was low, with events reported in only 2/33 patients (6.1%) in
the 2-step group and 1/36 patients (2.8%) in the 1-step group at
24 weeks. In a 24-week 2010 study by Seino et al. where liraglutide
monotherapy was evaluated, 8.2% and 13.4% of patients experienced
minor hypoglycemia (deﬁned as self-treatment by the patient) and
symptoms of hypoglycemia, respectively (Seino, Rasmussen, Nishida,
& Kaku, 2010). However, the different deﬁnitions for hypoglycemia
used in GetGoal-Mono-Japan and the study by Seino, Rasmussen,
Nishida, and Kaku (2010) should be noted. The current study used the
same deﬁnitions for symptomatic hypoglycemia as used in the entire
development program for lixisenatide (blood glucose b3.3 mmol/L
[60 mg/dL] and/or prompt recovery with oral carbohydrate, glucagon,
or intravenous glucose).
Evidence from this long-term safety study supports the use of a
2-step dose-increase regimen during the initiation of lixisenatide
treatment in Japanese patients, as patients in the 2-step group had a
lower incidence of nausea compared with the 1-step group. Minor
reductions in SBP were observed during the trial, and at the end of the
study blood pressure remained stable, though the signiﬁcance of these
changes could not be assessed in the descriptive analysis presented
here. Laboratory assessments did not reveal any abnormal ﬁndings.
Finally, no safety signal speciﬁc to patients in Japan was observed.
HbA1c levels decreased primarily during the initial weeks of
treatment up to week 24 (−0.99% [2-step group] and−0.74% [1-step
group]), and weremaintained during the entire 76-week study period
(−0.72%). Similar reductions were observed in the GetGoal-L-Asia
study at week 24 (least squares [LS] mean change: −0.77%) (Seino,
Min, Niemoeller, Takami, & Investigators, 2012). Lixisenatide treat-
ment was associated with improvements in FPG levels at week 24 and
at the end of the 76-week study period. This magnitude of reduction
in FPG (−1.16 and −0.56 mmol/L at week 24) was consistent with
that observed in the GetGoal-Mono and GetGoal-L-Asia trials (LS
mean change: −0.66 mmol/L [2-step group] and −0.87 mmol/L
[1-step group] for GetGoal-Mono versus −0.42 mmol/L for GetGoal-
L-Asia). Characteristically of an Asian population, most patients in the
present study were non-obese, but nevertheless there was a modest
reduction in body weight at week 24, which was more marked at the
end of the whole study period (−1.58 kg). The ﬁndings of the present
1309Y. Seino et al. / Journal of Diabetes and Its Complications 29 (2015) 1304–1309study in Japanese patients are consistentwith those of the predominantly
Caucasian population in the previous 12-week GetGoal-Mono study.
In that trial, lixisenatide administered as monotherapy signiﬁcantly
improvedglycemic control, andwas safe andwell tolerated (Fonsecaet al.,
2012).
A limitation of the current trial was its open-label design with no
placebo comparator arm. However, the design was considered appropri-
ate given that the objective of the study was to assess long-term safety
and tolerability.
5. Conclusions
The current study shows that lixisenatide monotherapy adminis-
tered once daily in Japanese patients with T2DM was well tolerated,
with less nausea with the 2-step regimen. Furthermore, lixisenatide
treatment was associated with beneﬁcial effects on HbA1c, FPG, and
body weight. This suggests a role for once-daily lixisenatide adminis-
tration in a 2-step dose-increase regimen as a favorable treatment
option for Japanese patients with T2DM.
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